Combination therapy doubles survival in metastatic lung cancer

The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial.
Latest Science News — ScienceDaily

Play
Arrow
Arrow
Slider